Abstract:Abstract Background Identifying immunogens which can elicit effective T cell responses against human immunodeficiency virus type 1 (HIV-1) is important for developing a T-cell based vaccine. It has been reported that human leukocyte antigen (HLA)-B*13-restricted T-cell responses contributed to HIV control in subtype B′ and C infected individuals. However, the kinetics of B*13-restricted T-cell responses, viral evolution within epitopes, and the impact on disease progression in CRF01_AE subtype HIV-1-infected men who have sex with men (MSM) are not known. Results Interferon-γ ELISPOT assays and deep sequencing of viral RNAs were done in 14 early HLA-B*13-positive CRF01_AE subtype HIV-1-infected MSM. We found that responses to RQEILDLWV (Nef 106–114 , RV9), GQMREPRGSDI (Gag 226–236 , GI11), GQDQWTYQI (Pol 487–498 , GI9), and VQNAQGQMV (Gag 135–143 , VV9) were dominant. A higher relative magnitude of Gag-specific T-cell responses, contributed to viral control, whereas Nef-specific T-cell responses were associated with rapid disease progression. GI11 (Gag) was conserved and strong GI11 (Gag)-specific T-cell responses showed cross-reactivity with a dominant variant, M228I, found in 3/12 patients; GI11 (Gag)-specific T-cell responses were positively associated with CD4 T-cell counts ( R = 0.716, P = 0.046). Interestingly, the GI9 (Pol) epitope was also conserved, but GI9 (Pol)-specific T-cell responses did not influence disease progression ( P > 0.05), while a D490G variant identified in one patient did not affect CD4 T-cell counts. All the other epitopes studied [VV9 (Gag), RQYDQILIEI (Pol 113–122 , RI10), HQSLSPRTL (Gag 144–152 , HL9), and RQANFLGRL (Gag 429–437, RL9)] developed escape mutations within 1 year of infection, which may have contributed to overall disease progression. Intriguingly, we found early RV9 (Nef)-specific T-cell responses were associated with rapid disease progression, likely due to escape mutations. Conclusions Our study strongly suggested the inclusion of GI11 (Gag) and exclusion of RV9 (Nef) for T-cell-based vaccine design for B*13-positive CRF01_AE subtype HIV-1-infected MSM and high-risk individuals.

Immunogenicity Comparison Between Codon Optimized HIV-1 CRF BC_07 Gp140 and Gp145 Vaccines.

Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines.

Immunogenicities and comparison of DNA vaccines encoding pol genes derived from B｀/C and A/E recombinant HIV-1 strains

Immunogenicity of DNA Vaccines Encoding Structural Proteins and Regulatory/accessory Proteins Derived from an HIV-1 CRF01_AE Isolate Circulating in China

Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes.

[Immunogenicity of Plasmid DNA and Adenoviral Vectors Encoding HIV-1 Subtype B Env Gene].

[Characterization of the HIV-1 Subunit Vaccine Containing the Gp41 NHR Domain of the HIV-1 CRF01_AE Recombinant Subtype in China].

Exploration of a Sequential Gp140-Gp145 Immunization Regimen with Heterologous Envs to Induce a Protective Cross-Reactive HIV Neutralizing Antibody Response In Non-human Primates

Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.

Comparison of the Immunogenicity of HIV-1 CRF07_BC Gag Antigen with or Without a Seven Amino Acid Deletion in P6 Region

Influence of HIV-1CN54 Gp145 deglycosylation on its immunogenicity

Immunogenicity of DNA Vaccines Encoding Regulatory/accessory Proteins Derived from Three Different Prevalent Strains in China

Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140

Expression of recombinant plasmid of HIV-1 gp120 and IFN-gamma in E. coli and its immunoregulatory effect]

Genetic and Neutralization Sensitivity of Diverse HIV-1 env Clones from Chronically Infected Patients in China

Genetic and Phenotypic Analysis of CRF01_AE HIV-1envClones from Patients Residing in Beijing, China

[Immunogenicity of Recombinant Adeno-Asscociated Virus Type 1 Expressing HIV-1 Gp120 Gene in Mice and Rhesus Macaques].

Single N277A Substitution in C2 of Simian Immunodeficiency Virus Envelope Influences Vaccine-Elicited CD4i Neutralizing and Anti-V2 Antibody Responses.

Deglycosylation of Hiv-1 Ae Gp140 Enhances the Capacity to Elicit Neutralizing Antibodies Against the Heterologous Hiv-1 Clade

Cross-neutralizing antibody profile of Chinese HIV-1-infected individuals and the viral envelope features from elite neutralizers

A longitudinal analysis of immune escapes from HLA-B*13-restricted T-cell responses at early stage of CRF01_AE subtype HIV-1 infection and implications for vaccine design